Baxter

US-based Baxter International has acquired German biopharmaceutical firm SuppreMol for around €200m ($225m).

SuppreMol develops treatment options for autoimmune and allergic diseases.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

Baxter BioScience president Ludwig Hantson said: "SuppreMol’s portfolio of novel investigational treatments complements and builds upon our leading and differentiated immunology portfolio, offering the opportunity to expand into new areas with significant market potential and unmet medical needs in autoimmune diseases."

Under the deal, Baxter has acquired SuppreMol’s early stage development portfolio of biologic immunoregulatory therapeutics to treat autoimmune diseases.

"The product portfolio focuses on the modulation of Fc receptor signaling pathways, an immune target that is expected to have a wide range of applications in autoimmune disorders."

The product portfolio focuses on the modulation of Fc receptor signaling pathways, an immune target that is expected to have a wide range of applications in autoimmune disorders.

The company will continue to operate SuppreMol’s operations in Munich, in addition to the portfolio.SuppreMol’s pipeline comprises lead candidate SM101, an investigational immunoregulatory treatment that completed Phase IIa studies in idiopathic thrombocytopenic purpura(ITP, a disorder causing low platelet levels) and systemic lupus erythematosus (SLE, a disorder in which the immune system attacks healthy tissue).

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

The trial’s data demonstrated a dose response in multiple endpoints among patients with SLE treated with either one of two different doses of SM101 for six months, according to Baxter.

In addition, the pipeline includes technologies with potential therapeutic applications in other autoimmune diseases and IgE-mediated allergic diseases.

SuppreMol CEO Dr Klaus Schollmeier said: "Working with Baxter, a global immunology leader, is the ideal setting for SuppreMol’s promising therapeutic projects to deliver on our most ambitious goal to treat important autoimmune diseases and severe allergies."

Image: Baxter building in Vienna. Photo: courtesy of Gerd Fahrenhorst.

Pharmaceutical Technology Excellence Awards - Nominations Closed

Nominations are now closed for the Pharmaceutical Technology Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.

Excellence in Action
Awarded the 2025 Pharmaceutical Technology Excellence Award for Business Expansion in Integrated Manufacturing, Upperton Pharma Solutions is rapidly expanding its UK GMP and sterile manufacturing footprint. Find out how Upperton’s integrated CDMO model helps pharma companies move from early development to clinical and niche commercial supply with fewer handovers and faster timelines.

Discover the Impact